Paige Mahaney - Oct 28, 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Scientific Officer
Signature: /s/ Shagha Russell, Attorney-in-Fact
Stock symbol: CCCC
Transactions as of: Oct 28, 2024
Transactions value $: $0
Form type: 4
Date filed: 10/29/2024, 04:31 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+76.8K		$0.00	76.8K	Oct 28, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+346K		$0.00	346K	Oct 28, 2024	Common Stock	346K	$6.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on October 28, 2025, subject to the Reporting Person's continued service on each such vesting date.
F2	25% of the shares underlying this option shall vest and become exercisable on October 28, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.